SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2018

Segment revenues and profits were as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
(in millions)	2018			2017			2018			2017
Revenues:
Bausch + Lomb/International	$	1,147		$	1,234		$	3,459		$	3,591
Salix	460			452			1,323			1,141
Ortho Dermatologics	177			177			460			556
Diversified Products	352			356			1,017			1,273
	$	2,136		$	2,219		$	6,259		$	6,561

Segment profits:
Bausch + Lomb/International	$	341		$	381		$	988		$	1,078
Salix	304			277			868			677
Ortho Dermatologics	89			73			193			264
Diversified Products	266			251			763			859
	1,000			982			2,812			2,878
Corporate	(167		)	(126		)	(442		)	(432		)
Amortization of intangible assets	(658		)	(657		)	(2,142		)	(1,915		)
Goodwill impairments	—			(312		)	(2,213		)	(312		)
Asset impairments	(89		)	(406		)	(434		)	(629		)
Restructuring and integration costs	(3		)	(6		)	(16		)	(42		)
Acquired in-process research and development costs	—			—			(1		)	(5		)
Acquisition-related contingent consideration	19			238			23			297
Other (expense) income, net	15			325			4			584
Operating income (loss)	117			38			(2,409		)	424
Interest income	3			3			9			9
Interest expense	(420		)	(459		)	(1,271		)	(1,392		)
Loss on extinguishment of debt	—			(1		)	(75		)	(65		)
Foreign exchange and other	—			19			18			87
Loss before (provision for) benefit from income taxes	$	(300	)	$	(400	)	$	(3,728	)	$	(937	)

Revenues by segment and product category were as follows:



	Three Months Ended September 30, 2018										Three Months Ended September 30, 2017
(in millions)	Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total		Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total
Pharmaceuticals	$	222	$	460	$	140	$	233	$	1,055	$	241	$	452	$	140	$	272	$	1,105
Devices	365		—		29		—		394		367		—		25		—		392
OTC	352		—		—		—		352		397		—		—		—		397
Branded and Other Generics	192		—		—		115		307		213		—		—		79		292
Other revenues	16		—		8		4		28		16		—		12		5		33
	$	1,147	$	460	$	177	$	352	$	2,136	$	1,234	$	452	$	177	$	356	$	2,219

	Nine Months Ended September 30, 2018										Nine Months Ended September 30, 2017
(in millions)	Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total		Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total
Pharmaceuticals	$	667	$	1,323	$	348	$	712	$	3,050	$	722	$	1,140	$	448	$	1,016	$	3,326
Devices	1,117		—		90		—		1,207		1,049		—		75		—		1,124
OTC	1,046		—		—		—		1,046		1,153		—		—		—		1,153
Branded and Other Generics	576		—		—		294		870		613		—		—		246		859
Other revenues	53		—		22		11		86		54		1		33		11		99
	$	3,459	$	1,323	$	460	$	1,017	$	6,259	$	3,591	$	1,141	$	556	$	1,273	$	6,561

Revenues are attributed to a geographic region based on the location of the customer were as follows:



	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2018		2017		2018		2017
U.S. and Puerto Rico	$	1,329	$	1,306	$	3,766	$	3,945
China	91		90		273		240
Canada	78		83		231		238
Japan	59		58		165		166
Poland	49		51		164		147
France	46		41		159		142
Mexico	56		54		153		144
Egypt	45		41		134		116
Germany	38		39		130		119
Russia	38		57		106		148
United Kingdom	29		29		87		79
Italy	19		19		64		58
Spain	17		17		61		55
Other	242		334		766		964
	$	2,136	$	2,219	$	6,259	$	6,561

Customers that accounted for 10% or more of total revenues consist of:



	Nine Months Ended September 30,
	2018	2017
AmerisourceBergen Corporation	18%	15%
McKesson Corporation (including McKesson Specialty)	18%	20%
Cardinal Health, Inc.	13%	13%